Related Experiment Video
Updated: Jul 6, 2026
08:13
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Treatment options for Duchenne muscular dystrophy
Emma Ciafaloni1, Richard T Moxley
1Department of Neurology, University of Rochester, 601 Elmwood Avenue, Box 673, Rochester, NY 14642, USA. emma_ciafaloni@urmc.rochester.edu
Current Treatment Options in Neurology
|March 13, 2008
Summary
Corticosteroid therapy, primarily prednisone, is the sole effective pharmacologic treatment for Duchenne muscular dystrophy (DMD), improving strength and slowing disease progression. Early intervention with physical, occupational, and orthopedic specialists is crucial for managing complications and maximizing patient independence.
Area of Science:
- Neurology
- Pediatrics
- Rehabilitation Medicine
Background:
- Duchenne muscular dystrophy (DMD) is a progressive genetic disorder characterized by muscle degeneration.
- Key treatment goals include maintaining ambulation and managing complications like scoliosis and respiratory issues.
Purpose of the Study:
- To outline the current management strategies for Duchenne muscular dystrophy.
- To emphasize the role of pharmacologic and multidisciplinary interventions in improving patient outcomes.
Main Methods:
- Review of existing literature on Duchenne muscular dystrophy treatment.
- Discussion of corticosteroid therapy (prednisone, deflazacort) efficacy and administration.
- Highlighting the importance of a multidisciplinary team approach.
Main Results:
- Corticosteroid therapy, particularly daily prednisone, is the only effective pharmacologic treatment, enhancing muscle strength and pulmonary function.
- Multidisciplinary care involving physical, occupational, orthopedic, and pulmonary specialists is essential for comprehensive management.
- Cognitive and behavioral symptoms require individualized management plans.
Conclusions:
- Corticosteroid treatment should be offered to all DMD patients after thorough discussion of benefits and risks.
- Early and ongoing involvement of a multidisciplinary team is critical for optimizing quality of life and functional independence in DMD patients.
- Palliative care is paramount in the late stages of the disease.
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...